Mammal heart tissue has long been assumed to be the exclusive domain of the M(2) subtype of muscarinic receptor, but data supporting the presence of other subtypes also exist. We have tested the hypothesis that muscarinic receptors other than the M(2) subtype are present in the heart as minor populations. We used several approaches: a set of competition binding experiments with pirenzepine, AFDX-116, 4-DAMP, PD 102807, p-F-HHSiD, AQ-RA 741, DAU 5884, methoctramine and tripinamide, blockage of M(1) muscarinic receptors using MT7 toxin, subtype-specific immunoprecipitation experiments and determination of phospholipase C activity. We also attempted to block M(1)-M(4) receptors using co-treatment with MT7 and AQ-RA 741. Our results show that only the M(2) subtype is present in the atria. In the ventricles, however, we were able to determine that 20% (on average) of the muscarinic receptors were subtypes other than M(2), with the majority of these belonging to the M(1) subtype. We were also able to detect a marginal fraction (6 +/- 2%) of receptors that, based on other findings, belong mainly to the M(5) muscarinic receptors. Co-treatment with MT7 and AQ-RA 741 was not a suitable tool for blocking of M(1)-M(4) receptors and can not therefore be used as a method for M(5) muscarinic receptor detection in substitution to crude venom. These results provide further evidence of the expression of the M(1) muscarinic receptor subtype in the rat heart and also show that the heart contains at least one other, albeit minor, muscarinic receptor population, which most likely belongs to the M(5) muscarinic receptors but not to that of the M(3) receptors.

Institute of Physiology 1st Faculty of Medicine Charles University Albertov 5 12800 Prague Czech Republic

Zobrazit více v PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct;368(4):316-9 PubMed

Mol Pharmacol. 1991 Nov;40(5):783-9 PubMed

Biochim Biophys Acta. 1988 Mar 11;968(3):340-5 PubMed

Cell Mol Life Sci. 2000 Jan 20;57(1):175-80 PubMed

Circ Res. 1996 Jul;79(1):86-93 PubMed

Pharmacol Res. 2001 Sep;44(3):161-82 PubMed

Mol Pharmacol. 1991 Jul;40(1):28-35 PubMed

Mol Pharmacol. 1993 Feb;43(2):149-57 PubMed

Eur J Pharmacol. 1993 Dec 7;250(2):223-30 PubMed

Eur J Pharmacol. 1994 Mar 3;253(3):275-81 PubMed

J Biol Chem. 2001 Feb 23;276(8):5650-8 PubMed

Pharmacol Rev. 1998 Jun;50(2):279-90 PubMed

Pediatr Res. 1992 Jun;31(6):601-5 PubMed

Toxicon. 2000 Feb;38(2):187-98 PubMed

Auton Autacoid Pharmacol. 2007 Jan;27(1):1-11 PubMed

Neuroscience. 1993 Oct;56(4):1041-8 PubMed

Mol Pharmacol. 1991 Dec;40(6):900-7 PubMed

Br J Pharmacol. 2000 Oct;131(3):447-52 PubMed

Br J Pharmacol. 2003 Jan;138(1):156-60 PubMed

J Basic Clin Physiol Pharmacol. 1993 Jul-Sep;4(3):229-48 PubMed

Biochem Pharmacol. 1997 Apr 4;53(7):959-67 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):366-76 PubMed

Biochim Biophys Acta. 1990 Oct 15;1055(1):43-53 PubMed

J Neurosci. 1991 Oct;11(10):3218-26 PubMed

Circulation. 2001 Mar 27;103(12):1638-43 PubMed

Br J Pharmacol. 2004 Jun;142(3):395-408 PubMed

Br J Pharmacol. 1995 Aug;115(8):1525-31 PubMed

Mol Pharmacol. 1983 Nov;24(3):351-6 PubMed

Br J Pharmacol. 2000 May;130(1):13-21 PubMed

FASEB J. 2004 Apr;18(6):711-3 PubMed

Eur J Pharmacol. 1992 Feb 13;225(2):105-12 PubMed

Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1692-7 PubMed

Mol Pharmacol. 2001 May;59(5):1029-36 PubMed

Br J Pharmacol. 1999 Aug;127(7):1551-8 PubMed

J Neurochem. 1999 Aug;73(2):780-90 PubMed

Ann N Y Acad Sci. 2004 Jun;1018:315-22 PubMed

Mol Pharmacol. 2002 Jun;61(6):1267-72 PubMed

Mol Pharmacol. 1991 May;39(5):643-9 PubMed

Mol Pharmacol. 1998 Mar;53(3):573-89 PubMed

J Cardiovasc Pharmacol. 1996 Apr;27(4):455-61 PubMed

Basic Res Cardiol. 2001 Nov;96(6):528-38 PubMed

Life Sci. 2006 Jun 6;79(2):112-20 PubMed

J Pharmacol Exp Ther. 2002 Apr;301(1):129-37 PubMed

J Physiol. 1993 Nov;471:41-60 PubMed

Am J Physiol. 1993 Sep;265(3 Pt 1):C666-73 PubMed

Br J Pharmacol. 2005 Aug;145(8):1153-9 PubMed

Mol Pharmacol. 1999 Mar;55(3):497-507 PubMed

Life Sci. 1997;60(13-14):1105-12 PubMed

J Lipid Mediat Cell Signal. 1995 Jul;12(1):1-10 PubMed

Circ Res. 1994 Nov;75(5):813-20 PubMed

J Biol Chem. 1998 Nov 27;273(48):32158-66 PubMed

FEBS Lett. 1990 Nov 26;275(1-2):65-9 PubMed

Pharmacol Res. 2006 Nov;54(5):345-55 PubMed

J Med Chem. 1998 Oct 8;41(21):4150-60 PubMed

Mol Pharmacol. 1988 Sep;34(3):327-33 PubMed

Br J Pharmacol. 2003 Feb;138(3):469-80 PubMed

Biochemistry. 1989 Aug 22;28(17):7130-7 PubMed

Mol Pharmacol. 1993 Dec;44(6):1171-5 PubMed

Muscarinic Receptors in Cardioprotection and Vascular Tone Regulation

Multitargeting nature of muscarinic orthosteric agonists and antagonists

Autoradiography of 3H-pirenzepine and 3H-AFDX-384 in Mouse Brain Regions: Possible Insights into M1, M2, and M4 Muscarinic Receptors Distribution

Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment

Decrease in heart adrenoceptor gene expression and receptor number as compensatory tool for preserved heart function and biological rhythm in M(2) KO animals